Contineum Therapeutics, Inc. Class A Common StockCTNMNASDAQ
Loading
EPS Growth AcceleratingAccelerating
Percentile Rank50
3Y CAGR-69.2%
Studio
Year-over-Year Change

Year-over-year earnings per share growth rate

3Y CAGR
-69.2%/yr
Annual compound
Percentile
P50
Within normal range
vs 3Y Ago
0x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
20250.46%
2024-342.22%
2023192.78%
202215.65%
20210.00%